Literature DB >> 950320

CGP 9000: a new orally active, broad-spectrum cephalosporin.

O Zak, W A Vischer, C Schenk, W Tosch, W Zimmermann, J Regös, E R Suter, F Kradolfer, J Gelzer.   

Abstract

CGP 9000, (7-[D-2-amino-2-(1,4-cyclohexadienyl)-acetamido]-3-methoxy-3-cephem-4-carboxylic acid), is a new broad-spectrum cephalosporin antibiotic. Its antibacterial activity in vitro (MIC) is similar, but its bactericidal efficacy superior to that of cephalexin and cephradine. Upon oral administration to mice infected with various bacteria, CGP 9000 is, in general, 2 to 7 times more effective than either cephalexin or cephradine.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 950320     DOI： 10.7164/antibiotics.29.653

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  10 in total

1.  Governmental toxicology regulations: an encumbrance to drug research?

Authors:  J Gelzer
Journal:  Arch Toxicol       Date:  1979-10       Impact factor: 5.153

2.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  A randomized double-blind investigation of cefroxadine (CGP 9000) versus cephalexin in urinary tract infection.

Authors:  J Hess; P Gammelgaard; B Holst; F Rasmussen; V F Thomsen
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

4.  Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans.

Authors:  J B Lecaillon; J L Hirtz; J P Schoeller; G Humbert; W Vischer
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  Pharmacokinetics of cefroxadin (CGP 9000) in man.

Authors:  A Gerardin; J B Lecaillon; J P Schoeller; G Humbert; J Guibert
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

6.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of T-2588, a new oral cephalosporin, compared with those of other oral beta-lactam antibiotics.

Authors:  S Okamoto; Y Hamana; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

8.  Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.

Authors:  M J Nieto; J M Lanao; A Dominguez-Gil; J M Tabernero; J F Macias
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Activity of cefroxadine and cephalexin in urinary tract infections: a double-blind comparative study.

Authors:  T Ahrens; K G Naber
Journal:  Infection       Date:  1983 Jan-Feb       Impact factor: 3.553

10.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.